Roivant Sciences (NASDAQ:ROIV) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Roivant Sciences (NASDAQ:ROIV) in a research note published on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock.

Separately, Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Roivant Sciences presently has a consensus rating of “Buy” and an average price target of $17.93.

Roivant Sciences Trading Down 2.8 %

Roivant Sciences stock opened at $10.49 on Tuesday. Roivant Sciences has a 52 week low of $9.76 and a 52 week high of $13.06. The stock has a market cap of $7.64 billion, a P/E ratio of 1.86 and a beta of 1.25. The stock has a 50 day moving average of $11.48 and a 200-day moving average of $11.60.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. As a group, equities analysts predict that Roivant Sciences will post -1.19 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company’s stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CIO Mayukh Sukhatme sold 412,584 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the transaction, the executive now directly owns 18,836,547 shares of the company’s stock, valued at approximately $226,980,391.35. This trade represents a 2.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,942,629 shares of company stock worth $23,034,486 over the last quarter. 7.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently made changes to their positions in the company. Gladius Capital Management LP bought a new position in Roivant Sciences in the 3rd quarter worth approximately $35,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the period. Finally, Quarry LP grew its position in Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.